Alzheimer's dementia:

Indications for: ADUHELM

Alzheimer's disease in mild cognitive impairment or mild dementia.

Adult Dosage:

See full labeling. Initiate titration based on dosing schedule. Give by IV infusion over 1hr every 4 weeks. Infusions 1 and 2: 1mg/kg. Infusions 3 and 4: 3mg/kg. Infusions 5 and 6: 6mg/kg. Infusion 7 and beyond: 10mg/kg.

Children Dosage:

Not established.

ADUHELM Warnings/Precautions:

Risk for amyloid related imaging abnormalities (ARIA), either with edema (ARIA-E), or with hemosiderin deposition (ARIA-H). Consider testing for ApoE ε4 carrier status to determine the risk for ARIA prior to treatment initiation. Risk for intracerebral hemorrhage: prior intracerebral hemorrhage >1cm in diameter, >4 microhemorrhages, superficial siderosis, history of diffuse white matter disease. Perform clinical evaluation if ARIA symptoms occur (esp during titration), including MRI testing if indicated. Obtain recent MRI (within 1yr) prior to initiation, and prior to 5th, 7th, 9th, and 12th infusions. Discontinue if hypersensitivity reactions occur. Pregnancy. Nursing mothers.

ADUHELM Classification:

Amyloid beta-directed antibody.

ADUHELM Interactions:

Caution when considering concomitant antithrombotics or a thrombolytic agent (eg, tissue plasminogen activator).

Adverse Reactions:

ARIA-Edema, headache, ARIA-H microhemorrhage, ARIA-H superficial siderosis, fall; hypersensitivity reactions.


Catabolic pathways.

Drug Elimination:

Half-life: 24.8 days.

Generic Drug Availability:


How Supplied:

Single-dose vial (1.7mL, 3mL)—1